Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Loredana Puca Clear advanced filters

  • Enhancer of zeste homolog 2 (EZH2) has been implicated as a driver of disease progression and resistance to hormonal therapies. Here, the authors focus on EZH2 in two subtypes of advanced prostate cancer and report how it modulates the bivalent genes thereby leading to forward differentiation after being targeted in neuroendocrine prostate cancer.

    • Varadha Balaji Venkadakrishnan
    • Adam G. Presser
    • Himisha Beltran
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-15

  • While many treatments for prostate cancer suppress the androgen receptor it becomes reactivated during disease progression. Here, the authors show that a KLF5 transcriptional programme is also activated during treatment and promotes migration and the appearance of a basal cell phenotype.

    • Meixia Che
    • Aashi Chaturvedi
    • Scott M. Dehm
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-15

  • The differentiation of prostate adenocarcinoma to neuroendocrine prostate cancer (CRPC-NE) is a mechanism of resistance to androgen deprivation therapy. Here the authors show that SWI/SNF chromatin-remodeling complex is deregulated in CRPC-NE and that the complex interacts with different lineage specific factors throughout prostate cancer transdifferentiation.

    • Joanna Cyrta
    • Anke Augspach
    • Mark A. Rubin
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-16

  • Neuroendocrine prostate cancer (NEPC) is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, resulting in resistance to AR-targeted therapy. Here they report ONECUT2 to drive NEPC tumorigenesis via regulation of hypoxia signaling and tumor hypoxia, and find hypoxia directed therapy to be effective in NEPC.

    • Haiyang Guo
    • Xinpei Ci
    • Housheng Hansen He
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-13

  • There are few available models to study neuroendocrine prostate cancer. Here they develop and characterize patient derived organoids from metastatic lesions, use these models to show the role of EZH2 in driving neuroendocrine phenotype, and perform high throughput organoid screening to identify therapeutic drug combinations.

    • Loredana Puca
    • Rohan Bareja
    • Himisha Beltran
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-10

  • Genome-wide DNA methylation analysis of metastatic biopsies from patients with castration-resistant prostate cancer reveals marked epigenetic differences between samples with adenocarcinoma and neuroendocrine histologies.

    • Himisha Beltran
    • Davide Prandi
    • Francesca Demichelis
    Research
    Nature Medicine
    Volume: 22, P: 298-305